Replies to post #456 on Camaro1093 Stocks!

[TH_Stockhunter]

POZN ($10.97)... Analyst thoughts on POZN and its potential for Vimovo approval!

Dr. Jonathan Aschoff, Ph.D., is a Senior Equity Analyst at Brean Murray, Carret & Co., LLC

http://finance.yahoo.com/news/Arthritis-Drug-Vimovo-twst-3473823072.html?x=0&.v=1